Dr. Straus has participated in clinical consultant meetings as well as acted as a speaker and author in continuing medical education activities supported by Ortho Biotech, for which he has received honoraria. He has also received small amounts of salary support to conduct investigator-initiated clinical trials supported by Ortho Biotech.
Quality-of-life and health benefits of early treatment of mild anemia
A randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies†
Article first published online: 14 SEP 2006
Copyright © 2006 American Cancer Society
Volume 107, Issue 8, pages 1909–1917, 15 October 2006
How to Cite
Straus, D. J., Testa, M. A., Sarokhan, B. J., Czuczman, M. S., Tulpule, A., Turner, R. R. and Riggs, S. A. (2006), Quality-of-life and health benefits of early treatment of mild anemia. Cancer, 107: 1909–1917. doi: 10.1002/cncr.22221
Clinical Investigators: 45–80 subjects: Fernando Cabanillas, MD, and Shirley A. Riggs, MD (University of Texas M. D. Anderson Cancer Center); Myron S. Czuczman, MD (Roswell Park Cancer Institute); David J. Straus, MD (Memorial Sloan-Kettering Cancer Institute); and Anil Tulpule, MD (USC Norris Cancer Center Hospital); 10–30 subjects: Hamid Al-Mondhiry, MD (Kissinger Health Systems); Philip Cohen, MD (Georgetown University Medical Center) John P. Greer, MD (Vanderbilt University Medical Center), Stephanie A. Gregory, MD (Rush University Medical Center), Sandra J. Horning, MD (Stanford University Medical Center), Joseph O. Moore, MD (Duke University Medical Center), Peter J. Rosen, MD (UCLA School of Medicine), and Todd M. Zimmerman, MD (University of Chicago); <10 subjects: Richard Ambinder MD (Johns Hopkins Hospital); James Berenson, MD (Cedars Sinai); Dennis Berman, MD (Chester County Hematology/Oncology Services); Reed E. Drews, MD (Beth Israel Deaconess Medical Center) David Irwin MD (Alta Bates Comprehensive Cancer Center); Sanford Kempin, MD (St. Vincent Comprehensive Cancer Center); Brad L. Pohlman, MD (Cleveland Clinic Taussig Cancer Center); Hussain I. Saba, MD (H. Lee Moffitt Cancer and Research Center); Robert S. Siegel, MD (George Washington University); and Mitchell R. Smith, MD (Fox Chase Cancer Center)
- Issue published online: 3 OCT 2006
- Article first published online: 14 SEP 2006
- Manuscript Accepted: 27 JUL 2006
- Manuscript Revised: 26 JUL 2006
- Manuscript Received: 1 MAR 2006
- Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ
- 8Relationship between hemoglobin levels and quality of life during radiation therapy plus concomitant or sequential chemotherapy in patients with cancer and anemia treated with epoetin alfa. J Natl Compr Cancer Netw. 2004; 2: 509–517., , .
- 11Cancer and treatment-related anemia. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology v. 2. 2006. Available at URL: http://www.nccn.org[ accessed August 28, 2006]., , , et al.
- 18Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. Evanston, IL: Evanston Northwestern Healthcare and Northwestern University; 1997..
- 22Cognitive effects of once weekly (QW) epoetin alfa in anemic patients (pts) with hematologic malignancies receiving chemotherapy (CT): interim results of the EPOLYM trial. Blood. 2004; 104: 609a. Abstract 2217., , , et al.
- 23Quality-of-life assessment in diabetes research: interpreting the magnitude and meaning of treatment effects. Diabetes Spect. 2000; 13: 36–41..
- 24Interpretation of quality of life outcomes: issues that affect magnitude and meaning. Med Care. 2000; 38( Suppl II): II–166–II–174..
- 30Biases in responding. Health Measurement Scales: A Practical Guide to Their Development and Use. 3rd ed. New York: Oxford University Press; 2003: 80–101., .